Kronox Lab Sciences Ltd
KRONOXKronox Lab Sciences Ltd is coiled. The quarters are improving, yet the P/E sits at the 33rd percentile of its own 2-year range — the business is moving before the market.
The sharpest disagreement: Foreign institutions moved −1.5 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced.
The price is in a confirmed uptrend (3 weeks in) while the P/E sits at the 33rd percentile of its own 2-year range. Underneath, the last four quarters read improving — profit +26.6% year on year, and 97% of the last 3 years' profit arrived as cash. What settles it: whether the register turns back in the story’s favour.
Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.
Kronox Lab Sciences Ltd trades at ₹152, in a confirmed uptrend and 3 weeks into that stage. That is +7.9% against its own 200-day average. It sits at 68% of a 52-week range of ₹132 to ₹161. On relative strength it has no relative-strength read yet.
Today the stock is in a confirmed uptrend — week 3 of stage 2, confirmed. At ₹152 it trades +7.9% versus its 200-day average and sits at 68% of its 52-week range (₹132–₹161).
Against the market, two honest reads. Cumulative: over the last 2 months the stock moved +15% while the NIFTY 500 moved +4% — ahead of the index over the full window. Recent form: no trailing-13-week read yet — the ribbon below is that same metric, week by week.
What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.
→ The trend is one thing; the bill is another. Are you paying up for it? Next: the P/E sits at the 33rd percentile of its own range.
Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.
Kronox Lab Sciences Ltd trades at 20.7× P/E, near the bottom of its own range — cheaper only 33% of the time. Its long-run median P/E is 23.1×, measured across 2.1 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.
Today's P/E of 20.7× is near the bottom of its own range — cheaper only 33% of the time, against a long-run median of 23.1× measured over 2.1 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.
One caveat before moving on: margins are the best this company has ever printed — cheap against its own history on record margins is not the same thing as cheap. If profitability mean-reverts, today's multiple is higher than it looks.
Put together: the multiple is low against its own past, so the story rests on the earnings line underneath it, not the multiple.
→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.
Stage: Mixed Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).
Kronox Lab Sciences Ltd reads as mixed on its fundamental arc. Mixed — no clean majority across the growth curves, ROCE slipping at 36.0% — the per-curve reads carry the story. The read is built from 9 quarters across 3 curves, on partial evidence.
Why it matters: when the curves disagree, the per-curve reads above matter more than any single verdict.
One or more growth curves carry a base-effect spike — a large year-on-year move off a near-zero or loss-making comparable quarter. Those spikes are capped before the classifier reads the trajectory, and shown pinned on the chart, so a single distorted quarter does not drive the stage call.
Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.
A partial read: at least one curve is short, or the returns curve is not the computed quarterly series — hold the stage word a little more loosely.
| 1yr | 3yr | 5yr | 10yr | |
|---|---|---|---|---|
| Revenue | +1.0% | +1.7% | +10.3% | — |
| Profit | +12.0% | +20.5% | +22.9% | — |
| EPS | +8.6% | +19.0% | −55.0% | — |
→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.
4-Factor Sector Score
56.1/100 — rank 11 of 27 in Speciality Chemicals · 61% evidence confidence
Kronox Lab Sciences Ltd scores 56.1 out of 100 against the 27 companies it is compared with in Speciality Chemicals, ranking 11. Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
The four contributions add to the total exactly: 13.7 + 20.3 + 11 + 11.1 = 56.1. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.
What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.
Revenue Revenue is the top line: everything the company billed its customers in the period.
Kronox Lab Sciences Ltd reported ₹26.1 Cr of revenue in the Mar 26 quarter, +0.0% year on year. Over 6 years it has compounded at 12.4% a year. The last full year, FY26, came in at ₹101 Cr. The last four reported quarters add to ₹101 Cr.
Kronox Lab Sciences Ltd reported ₹26.1 Cr of revenue in the Mar 26 quarter, +0.0% year on year. Over 6 years it has compounded at 12.4% a year. The last full year, FY26, came in at ₹101 Cr. The last four reported quarters add to ₹101 Cr.
FY26 revenue came in at ₹101 Cr (+1.0% on the year), capping 6 years at 12.4% compound. The latest quarter (Mar 26) printed ₹26.1 Cr, +0.0% year on year.
Pace check: the last four quarters averaged +1.1% growth against the decade's 12.4% — the current year is running slower than its own long-run rate.
Acceleration check: trailing-twelve-month revenue grew +1.0% over the last 4 quarters against +6.1%/yr over the last 8 — rolling over; TTM profit +8.2% vs +13.6%/yr — rolling over.
→ Revenue grew — did margins hold as it scaled? Next: 36.4% this quarter (+6.8 pp YoY).
Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.
Kronox Lab Sciences Ltd's operating margin is 36.4% in the Mar 26 quarter, +6.8 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 23.0% to 34.0%. The current quarter is running above every full year in that window.
Kronox Lab Sciences Ltd's operating margin is 36.4% in the Mar 26 quarter, +6.8 percentage points against the same quarter a year ago. That is the widest this company has ever printed on a full-year basis. Across 7 fiscal years the operating margin has ranged 23.0% to 34.0%. The current quarter is running above every full year in that window.
The latest quarter's operating margin is 36.4%, +6.8 pp against the same quarter a year ago. Across 7 fiscal years the operating margin has ranged 23.0%–34.0%, and FY26's 34.0% is the top of that band — a record year.
Why the margin moved: operating margin went +6.8 pp year on year while gross margin went +10.3 pp — the gain came mostly from the gross line: input costs and pricing.
Worth repeating from the valuation section: cheap against its own history on record margins is not the same thing as cheap — a record margin flatters every ratio built on top of it.
→ Margins held — did that reach the bottom line? Next: profit +26.6% in the latest quarter.
Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.
Kronox Lab Sciences Ltd earned ₹8.0 Cr of net profit in the Mar 26 quarter, +26.6% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹28.0 Cr. The 6-year compound rate is 20.8%. That is 30.6% of the quarter's revenue. The same quarter a year earlier earned ₹6.3 Cr.
Kronox Lab Sciences Ltd earned ₹8.0 Cr of net profit in the Mar 26 quarter, +26.6% year on year. It is the 7th consecutive quarter of growth. Full-year FY26 profit was ₹28.0 Cr. The 6-year compound rate is 20.8%. That is 30.6% of the quarter's revenue. The same quarter a year earlier earned ₹6.3 Cr.
Mar 26 profit was ₹8.0 Cr, +26.6% year on year — the 7th consecutive quarter of growth. On the full year, FY26 printed ₹28.0 Cr (+12.0%), and the 6-year compound rate is 20.8%.
Why profit moved: revenue contributed +0.0% and the margin +6.8 pp — the quarter was margin-led: most of the profit growth came from keeping more of each sale.
Pace comparison, last four quarters: profit +8.2% vs revenue +1.1%. Profit is growing faster than sales — fixed costs are being spread over a bigger base, and each extra rupee of revenue drops more to the bottom line.
→ Profit rose — but did the cash follow? Next: 97% of the last 3 years' profit arrived as cash.
Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.
Over the last 3 fiscal years 97% of Kronox Lab Sciences Ltd's reported profit arrived as operating cash — the cash follows the profit. In FY26 that was ₹24.0 Cr of operating cash against ₹28.0 Cr of profit. After ₹3.0 Cr of capital spending, ₹21.0 Cr was left as free cash.
FY26: operating cash of ₹24.0 Cr against reported profit of ₹28.0 Cr, leaving free cash of ₹21.0 Cr after ₹3.0 Cr of capital spending. Across the last 3 fiscal years the conversion rate is 97% of profit.
Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.
Why conversion sits at 97%: the cash cycle stretched 11 days between FY21 and FY26 — more of each rupee of profit waits inside the cycle before arriving.
Router verdict: the bigger cash user is investment — capital spending ran 4.5× depreciation over three years, so the next section's job is to check what that build-out is buying.
→ So follow the cash to where it goes. Next: ₹18.0 Cr of building over 3 years.
Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).
Kronox Lab Sciences Ltd's cash conversion cycle runs 90 days in FY26, up from 79 days in FY21. Capital spending ran ₹18.0 Cr over the last 3 years. At FY26 sales of ₹101 Cr each day of that cycle holds about ₹0.3 Cr, so roughly ₹25.0 Cr sits inside the business at any moment.
FY26: debtors at 76 days, inventory at 66 days — roughly 2.2 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of 90 days, looser than FY21's 79.
The full loop: cash goes out to suppliers and production on day 0; stock waits 66 days to sell; customers pay about 76 days after that; and suppliers themselves are paid at 52 days — netting out to the 90-day cycle.
In money terms: at FY26 sales of ₹101 Cr, each day of the cycle holds about ₹0.3 Cr — so the 90-day loop keeps roughly ₹25.0 Cr sitting inside the business at any moment.
On the investment side: capital spending of ₹18.0 Cr over the last 3 fiscal years against ₹4.0 Cr of depreciation — the company is building well ahead of wear-and-tear. Capital work-in-progress stands at ₹1.0 Cr (FY26) — capacity paid for but not yet earning.
The synthesis: the cash is going into capacity, not disappearing into the cycle — the question becomes whether the new capacity earns.
→ Does all this activity actually earn its cost of capital? Next: ROCE is 36% and the ROIC − WACC spread is +27.5 pp.
Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.
Kronox Lab Sciences Ltd earns a ROCE of 36% in FY26. Return on invested capital clears the cost of that capital by +27.5 percentage points, so growth here adds value rather than only size. The wiring behind it is 27.7% net margin on 0.79× asset turns.
FY26 ROCE is 36%.
Why the return is what it is — the wiring (FY26): 27.7% net margin × 0.79× asset turns × 1.10× balance-sheet leverage ≈ 24.1% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.
The capstone test — ROIC − WACC: 39.5% − 12.0% = a +27.5 pp spread. The 12.0% is a standing assumption for the cost of capital in India, not a per-stock estimate — read the sign and the size of the spread, not the decimals. A spread this wide means every rupee reinvested creates more than a rupee of value — the engine compounds.
→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.02.
Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.
Kronox Lab Sciences Ltd carries ₹2.0 Cr of borrowings against ₹116 Cr of equity in FY26, a debt-to-equity of 0.02. Over 5 years borrowings went from ₹4.0 Cr to ₹2.0 Cr. Capital spending ran ₹18.0 Cr across the last 3 of those years.
FY26: borrowings of ₹2.0 Cr against equity of ₹116 Cr — a debt-to-equity of 0.02. Over 5 years borrowings went from ₹4.0 Cr to ₹2.0 Cr while capital spending ran ₹18.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.
→ Who owns this, and are they adding or leaving? Next: Domestic institutions cut 2.3 points over 8 quarters.
Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.
Domestic institutions cut 2.3 points of Kronox Lab Sciences Ltd over 8 quarters, the biggest move on the register. That takes domestic institutions to 2.1% of the company. Foreign institutions moved −1.5 points over the same window, to 0.0%. The register is read on the four disclosed classes only; nothing is inferred between filings.
The register over the last two years — Domestic institutions: −2.3 points over 8 quarters to 2.1%; Foreign institutions: −1.5 points over 8 quarters to 0.0%; Promoters: +0.0 points over 8 quarters to 74.2%.
🚨 Why the register moved: domestic institutions drove it (−2.3 points), alongside foreign institutions (−1.5 points) — distribution into the market’s bid.
→ One last check: does the safety math agree? Next: the balance-sheet safety line.
Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.
Kronox Lab Sciences Ltd: the Z-score reads 32.38. A Z-score above roughly 3 reads as safe and below roughly 1.8 as the distress zone, so this sits well clear of distress. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure.
Why it matters: a Z-score of 32.38 sits well clear of the distress zone — the balance sheet is not the risk here.
The safety line in one sentence: the Z-score reads 32.38.
| Company | P/E | Mkt cap | Revenue | EPS | ROCE | Stage |
|---|---|---|---|---|---|---|
| Kronox Lab Sciences Ltd this page | 20.7× | ₹573 Cr | Mixed | |||
| Pidilite Industries Ltd | 64.9× | ₹1.6L Cr | Consistent | |||
| Aether Industries Ltd | 83.7× | ₹18,945 Cr | Mixed | |||
| Aarti Industries Ltd | 42.1× | ₹17,331 Cr | Turning around | |||
| Anupam Rasayan India Ltd | 83.6× | ₹14,226 Cr | Improving | |||
| Privi Speciality Chemicals Ltd | 42.9× | ₹14,044 Cr | Mixed | |||
| Vinati Organics Ltd | 30.4× | ₹13,478 Cr | Topping out | |||
| Alkyl Amines Chemicals Ltd | 48.3× | ₹9,153 Cr | No read | |||
| Clean Science & Technology Ltd | 33.4× | ₹7,663 Cr | Deteriorating | |||
| Galaxy Surfactants Ltd | 24.8× | ₹6,896 Cr | Mixed | |||
| Neogen Chemicals Ltd | 159.0× | ₹5,648 Cr | Mixed | |||
| Fineotex Chemical Ltd | 37.7× | ₹4,610 Cr | Turning around | |||
| Vishnu Chemicals Ltd | 29.9× | ₹4,257 Cr | Mixed | |||
| Tatva Chintan Pharma Chem Ltd | 76.9× | ₹4,029 Cr | Turning around | |||
| Yasho Industries Ltd | 147.0× | ₹3,704 Cr | Improving | |||
| Grauer & Weil (India) Ltd | 20.4× | ₹3,354 Cr | Turning around | |||
| Panama Petrochem Ltd | 14.2× | ₹3,014 Cr | Turning around | |||
| Fineotex Chemical Ltd | 28.3× | ₹2,551 Cr | Turning around | |||
| Thirumalai Chemicals Ltd | — | ₹2,022 Cr | No read | |||
| Paushak Ltd | 41.6× | ₹1,387 Cr | Mixed | |||
| Platinum Industries Ltd | 23.9× | ₹1,251 Cr | Improving | |||
| Amines & Plasticizers Ltd | 29.3× | ₹1,069 Cr | Topping out | |||
| Sunshield Chemicals Ltd | 35.5× | ₹1,051 Cr | Turning around | |||
| Vikram Thermo (India) Ltd | 20.0× | ₹768 Cr | Mixed | |||
| Sunshield Chemicals Ltd | 29.2× | ₹720 Cr | Turning around | |||
| DMCC Speciality Chemicals Ltd | 24.9× | ₹680 Cr | Mixed | |||
| Chemcon Speciality Chemicals Ltd | 27.4× | ₹647 Cr | Improving | |||
| Amal Ltd | 23.0× | ₹628 Cr | No read | |||
| Transpek Industry Ltd | 13.0× | ₹595 Cr | Deteriorating |
Frequently asked questions
What is Kronox Lab Sciences Ltd's share price today?
Kronox Lab Sciences Ltd trades at ₹152. The company is valued at ₹573 Cr. The stock sits at 68% of its 52-week range of ₹132–₹161, +7.9% versus its 200-day average. On the tape, the price is in a confirmed uptrend, 3 weeks in. — as of 24 July 2026.
What were Kronox Lab Sciences Ltd's latest quarterly results?
Kronox Lab Sciences Ltd reported revenue of ₹26.1 Cr and net profit of ₹8.0 Cr for the Mar 26 quarter. Revenue rose 0.0% and profit rose 26.6% year on year. Earnings per share were ₹2.16. The operating margin was 36.4%, 6.8 pp higher than a year earlier. — as of 24 July 2026.
What is Kronox Lab Sciences Ltd's revenue?
Kronox Lab Sciences Ltd reported revenue of ₹26.1 Cr in the Mar 26 quarter, +0.0% year on year. For the full FY26 fiscal year, revenue was ₹101 Cr (+1.0%). Over the last 6 years revenue compounded at 12.4% a year. — as of 24 July 2026.
What is Kronox Lab Sciences Ltd's profit?
Kronox Lab Sciences Ltd earned ₹8.0 Cr of net profit in the Mar 26 quarter, +26.6% year on year — the 7th straight quarter of growth. Full-year FY26 profit was ₹28.0 Cr. The operating margin ran 36.4% in the latest quarter. — as of 24 July 2026.
What is Kronox Lab Sciences Ltd's market cap?
Kronox Lab Sciences Ltd's market capitalisation is ₹573 Cr at a share price of ₹152. Market cap is the share price multiplied by shares outstanding, so it is restated whenever the price moves. — as of 24 July 2026.
What is Kronox Lab Sciences Ltd's P/E ratio?
Kronox Lab Sciences Ltd trades at a P/E of 20.7×, at the 33rd percentile of its own 2-year range, against a long-run median of 23.1×. This is a comparison with the stock's own history, not a value call — as of 24 July 2026.
Does Kronox Lab Sciences Ltd pay a dividend?
Yes — Kronox Lab Sciences Ltd's dividend payout was 7% of profit in FY26, and it recorded a payout in 3 of its last 7 reported fiscal years. This page holds the payout ratio, not a per-share amount. — as of 24 July 2026.
Is Kronox Lab Sciences Ltd overvalued?
On its own history, Kronox Lab Sciences Ltd looks cheap against its own history: its P/E of 20.7× has been cheaper only 33% of the time in 2 years (long-run median 23.1×). That is a percentile read against the stock's own past, not a price opinion or a direction call. One caveat: margins are the best this company has ever printed — cheap on record margins is not the same thing as cheap. — as of 24 July 2026.
Is Kronox Lab Sciences Ltd growing?
Yes — Kronox Lab Sciences Ltd is growing: latest-quarter revenue +0.0% year on year, profit +26.6%, and the margin +6.8 pp at 36.4%. The 6-year compound rates are 12.4% (revenue) and 20.8% (profit). The earnings engine currently reads: improving — as of 24 July 2026.
How is Kronox Lab Sciences Ltd performing?
Kronox Lab Sciences Ltd is in a confirmed uptrend, 3 weeks in. Its latest quarter's revenue rose 0.0% and profit rose 26.6% year on year. This describes what the data did, not a rating. — as of 24 July 2026.
What stage is Kronox Lab Sciences Ltd in?
Mixed — no clean majority across the growth curves, ROCE slipping at 36.0% — the per-curve reads carry the story. The read comes from the last 12 quarters of growth (revenue growth +0.0% latest, profit growth +26.6% latest) plus the ROCE curve, classified by deterministic rules — a trajectory read, not a buy or sell call — as of 24 July 2026.
Is Kronox Lab Sciences Ltd in an uptrend?
Yes — the price is in a confirmed uptrend (week 3 of stage 2), trading +7.9% versus its 200-day average and at 68% of its 52-week range. Price stages cycle base → advance → top → decline, and the stage names where this stock sits in that cycle — as of 24 July 2026.
Will Kronox Lab Sciences Ltd's share price go up?
This page publishes no price forecast for Kronox Lab Sciences Ltd. What it measures instead: the share price is ₹152, the price is in a confirmed uptrend 3 weeks in. Its P/E of 20.7× sits at the 33rd percentile of its own 2-year range. — as of 24 July 2026.
Who owns Kronox Lab Sciences Ltd?
Promoters hold 74.2% of Kronox Lab Sciences Ltd, foreign institutions 0.0%, domestic institutions 2.1% and the public 23.7% (latest quarter). The biggest move on the register over the last two years: Domestic institutions cut 2.3 points over 8 quarters. — as of 24 July 2026.
Does Kronox Lab Sciences Ltd have too much debt?
No — Kronox Lab Sciences Ltd's debt-to-equity is 0.02. FY26 borrowings were ₹2.0 Cr against equity of ₹116 Cr. The returns on this page are earned, not borrowed — as of 24 July 2026.
What is Kronox Lab Sciences Ltd's capex?
Kronox Lab Sciences Ltd spent ₹18.0 Cr on capital expenditure over the last 3 fiscal years, a figure derived from the change in fixed assets plus depreciation. In FY26 alone that was ₹3.0 Cr, with ₹1.0 Cr in capital work-in-progress — capacity paid for but not yet earning. — as of 24 July 2026.
What is Kronox Lab Sciences Ltd's cash flow?
Kronox Lab Sciences Ltd generated ₹24.0 Cr of operating cash flow in FY26 and ₹21.0 Cr of free cash flow after ₹3.0 Cr of capital spending. Reported profit that year was ₹28.0 Cr, so operating cash ran behind profit. Cash-flow resolution for India is annual. — as of 24 July 2026.
Is Kronox Lab Sciences Ltd's profit real cash?
Yes — over the last 3 fiscal years, 97% of Kronox Lab Sciences Ltd's reported profit arrived as operating cash. In FY26, operating cash was ₹24.0 Cr against reported profit of ₹28.0 Cr. The cash then goes mostly into building capacity. Cash-flow resolution is annual — as of 24 July 2026.
How financially safe is Kronox Lab Sciences Ltd?
On the balance sheet, the Z-score reads 32.38 — above roughly 3 is safe, below roughly 1.8 is the distress zone. That sits well clear of trouble. — as of 24 July 2026.
Where is Kronox Lab Sciences Ltd in its business cycle?
Kronox Lab Sciences Ltd's FY26 operating margin was 34.0%, against a 7-year band of 23.0%–34.0%: the top of the band — a record year. Record profitability is late-cycle territory: every ratio flatters at the top, and the story leans on margins holding. The latest quarter ran 36.4%. Profitability versus a company's own long band is the cleanest cycle clock this page holds — as of 24 July 2026.
What could break the Kronox Lab Sciences Ltd story?
The sharpest disagreement: Foreign institutions moved −1.5 points over 8 quarters while the operating story went the other way — someone close to the numbers is not convinced. Mechanically, two Friday closes in a row below the 200-day average would end the price trend — that is the exit rule this page tracks — as of 24 July 2026.
Is Kronox Lab Sciences Ltd a stock worth studying right now?
This is not investment advice. The machine read: Kronox Lab Sciences Ltd is coiled. The quarters are improving, yet the P/E sits at the 33rd percentile of its own 2-year range — the business is moving before the market. The sharpest open question: whether the register turns back in the story’s favour. Every number on this page is drawn deterministically from the raw series, with no forecasts and no price opinions — as of 24 July 2026.